Vascugen is dedicated to revolutionizing the standard of care for millions of patients suffering from severe conditions caused by restricted blood flow to tissues. Particularly for diabetic patients at high risk for limb amputation and associated morbidity. The company’s lead program is an induced-pluripotent stem cell (iPSC)-derived vasculogenic cell with the potential to forge new blood vessels in oxygen-starved tissues. Vascugen utilizes an integrated approach to advance therapeutic candidates from early R&D through to clinical (cGMP) manufacturing. By doing this they mitigate technology and tech transfer risks along the development chain. Embedded within their R&D facility is a state-of-the-art cleanroom designed to iPSC industry standards. Dedicated quality assurance (QA) and a quality management system (eQMS) are in place for compliance and product release. Where feasible, Vascugen deploys closed system manufacturing platforms in their processes.
This company will be presenting on Day 3 of DeepTechU 2022. View schedule >>